We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Abnormal Prenatal Blood Test Results Could Indicate Hidden Maternal Cancers

By LabMedica International staff writers
Posted on 05 Dec 2024

Researchers have discovered previously undiagnosed cancers in 48. More...

6% of pregnant individuals who received abnormal results from prenatal cell-free DNA (cfDNA) testing, which is typically used to screen for chromosomal disorders in the fetus. The types of cancers found included colorectal, breast, lung, and pancreatic cancers, as well as lymphoma, cholangiocarcinoma, and renal carcinoma. The cfDNA screening test analyzes placental DNA fragments circulating in the maternal bloodstream to identify an extra chromosome or determine the baby’s sex. In addition to detecting fetal DNA, cfDNA testing also identifies DNA released from the mother’s red blood stem cells, and occasionally, it can reveal abnormal DNA that may indicate an undiagnosed cancer in an asymptomatic pregnant individual. This study was published in the New England Journal of Medicine.

The ongoing IDENTIFY study by the National Institutes of Health (NIH, Bethesda, MD, USA) is investigating the implications of abnormal cfDNA test results that may suggest the presence of cancer. For the current analysis, the researchers screened 107 participants from the IDENTIFY study for cancer using whole-body magnetic resonance imaging (MRI), standard medical diagnostic tests, and cfDNA sequencing. Out of these participants, 52 were diagnosed with cancer. The researchers found that whole-body MRI was the most effective method for detecting cancer in this group.

Traditional diagnostic methods, such as reviewing medical history, assessing symptoms, and performing physical examinations, proved limited in detecting cancer or pinpointing its location. Other abnormal cfDNA results were found to be related to fibroids (benign tumors of the uterus), discrepancies between placental and fetal chromosomes, and clonal hematopoiesis in the mother (a precursor to blood cancers). The researchers emphasized the need for further studies to confirm the cfDNA sequencing patterns identified in this study, which could help detect cancer in pregnant individuals with no obvious clinical symptoms.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.